MultiHance outperforms Omniscan for enhancement of brain tumors

August 29, 2008 MultiHance outperforms Omniscan for enhancement of brain tumors H. A. Abella -------------------------------------------------------------------------------- Although both gadobenate dimeglumine and gadodiamide are gadolinium-based agents, the former provides more conspicuous enhancement for imaging of brain lesions, according to results from an international multicenter trial. Findings could lead to further improvements in the management of these patients. Neuroradiologists routinely perform MR imaging of central nervous system tumors using one of five gadolinium-based contrast agents approved by the FDA. These agents involve different chelating mechanisms around their gadolinium cores, but they share the ability to enhance areas of tumor activity. Accurate detection and characterization of these lesions guides patient management. This includes surgical guidance, delineation of proper target volumes for radiotherapy, and recurrence control.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC